Mesotheliom, MPM: Studien, Ergebnisse
Allgemeines
MARS (4)
MesoVAT
EMPHACIS
| Behandlungsarm | Gesamtgruppe | Patienten mit vollständiger Vitamingabe | ||||
| ALIMTA/ Cisplatin | Cisplatin | Statistik | ALIMTA/ Cisplatin | Cisplatin | Statistik | |
| Patienten | 226 | 222 | 168 | 163 | ||
| OS (Monate) | 12,1 (10,0-14,4) | 9,3 (7,8-10,7) | Log Rank p= 0,020 | 13,3 (11,4-14,9) | 10,0 (8,4-11,9) | Log Rank p = 0,051 |
| TTP (Monate) | 5,7 (4,9-6,5) | 3,9 (2,8-4,4) | Log Rank p= 0,001 | 6,1 (5,3-7,0) | 3,9 (2,8-4,5) | Log Rank p=0,008 |
| Zeit bis zum Therapieversagen (Monate) | 4,5 (3,9-4,9) | 2,7 (2,1 -2,9) | Log Rank p= 0,001 | 4,7 (4,3-5,6) | 2,7 (2,2-3,1) | Log Rank p=0,001 |
| Gesamtansprechrate | 41,3 % (34,8-48,1) | 16,7 % (12,0-22,2) | Fisher's exact p < 0,001 | 45,5 % (37,8-53,4) | 19,6 % (13,8-26,6) | Fisher's exact p < 0,001 |
LUME-Meso
Quellen
Phase II trial of trimodality therapy for malignant pleural mesothelioma (EORTC 08031).
Eur Respir J Eur 2010;36:1362-9
doi: 10.1183/09031936.00039510.
2.) Nakas A, et al.:
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.
Eur J Cardiothorac Surg 2012;41:1031–6.
3.) Yan TD, Boyer M, Tin MM, et al.:
Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors.
Gen Thorac Surg 2009;138: 619–24.
4.) Treasure T, Lang-Lazdunski L, Waller D, et al. for the MARS trialists:
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.
Lancet Oncol 2011;12:763–72.
5.) Vogelzang NJ, Rusthoven JJ, Symanowski J, et al.:
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
J Clin Oncol 2003;21:2636–44
6.) van Meerbeeck JP, Gaafar R, Manegold C, et al.:
European Organisation for Research and Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
J Clinic Oncol 2005;23:6881–9
7.) Muers MF, Stephens RJ, Fisher P, et al.:
MS01 Trail Management Group: active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trail.
Lancet 2008;371:1685–94
8.) Rusch VW, Rosenzweig K, Venkatraman E, et al.:
A phase II trail of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
J Thorac Cardiovasc Surg 2001;122: 788–95
9.) Gupta V, Mychalczak B, Krug L, et al.:
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
Int J Radiat Oncol Biol Phys 2005;63:1045–52
10.) Bille A, Belcher E, Raubenheimer H, et al.:
Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy`s and St Thomas` hospitals.
Gen Thorac Cardiovasc Surg 2012;60: 289–96.
11.) Sugarbaker DJ, Flores RM, Jaklitsch MT, et al.:
Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
J Thorac Cardiovasc Surg 1999;117: 54–63.
12.) Krug LM, Pass HI, Rusch VW, et al.:
Multicenter phase II trail of neoadjuvant Pemetrexed plus Cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
J Clinic Oncol 2009;27: 3007–13.
13.) Patel PR, Yoo S, Broadwater G, et al.:
Effect of increasing experience on dosimetric and clinical outcomes on the management of malignant pleural mesothelioma with intensity-modulated radiation therapy.
Int J Radiat Oncol Biol Phys 2012;83: 362–8.
14.) Bölükbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J:
Survival after trimodality therapy for malignant pleural mesothelioma: Radical pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
Lung Cancer 2011;71:75–81
